Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coeptis Therapeutics Holdings, Inc. - Common Stock (NQ:COEP)

9.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License
Via AB Newswire
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
From Coeptis Therapeutics
Via GlobeNewswire
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors 
From Coeptis Therapeutics
Via GlobeNewswire
Biotech Bright Spots: Coeptis Therapeutics (COEP) And 3 Hidden Treasures
Via Get News
COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology 
From Coeptis Therapeutics
Via GlobeNewswire
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating... 
From Coeptis Therapeutics
Via GlobeNewswire
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating... 
From Coeptis Therapeutics
Via GlobeNewswire
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech Innovation: Coeptis Therapeutics (COEP) And 3 Companies Changing The Game
Via Get News
These are the 4 hottest stocks insiders bought in January
Insiders are buying these stocks, but not all are good buys for investors or bullish traders; avoid stocks with high short interest, no revenue, and no earnings 
Via MarketBeat
Potential acquisition of VyGen-Bio would Strengthen Coeptis Therapeutics (NASDAQ: COEP) oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform
Via Get News
Acquisition Rights Obtained for Combinatorial Immuno-Oncology Treatments Using Multi-Antigen CAR T Technology, Cell Therapy for Multiple Cancers: Coeptis Therapeutics (NASDAQ: COEP)
Via Get News
BioMedNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal
Via Investor Brand Network
Translational Medicine Journal Features Multi-Antigen CAR T Technology, Cell Therapy, and In Vitro Diagnostics with Multiple Cancer Types: Coeptis Therapeutics Holdings, Inc (NASDAQ: COEP)
Via Get News
Coeptis Therapeutics Holdings, Inc (NASDAQ: COEP) to Collaborate with the University of Pittsburgh to expand pre-clinical Development of SNAP-CAR T Cells Targeting HER2-Positive Cancers
Via Get News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.